Table of Contents Author Guidelines Submit a Manuscript
Journal of Cancer Epidemiology
Volume 2015 (2015), Article ID 203284, 7 pages
http://dx.doi.org/10.1155/2015/203284
Research Article

Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast

1Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA
2Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London W2 1PG, UK
3Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
4David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
5Department of Oncology, McGill University, Montreal, QC, Canada H3A 0G4
6Population Studies and Prevention Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
7Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

Received 6 February 2015; Accepted 12 May 2015

Academic Editor: Brian Cox

Copyright © 2015 Chelsea Catsburg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Atypical hyperplasia of the breast (AH) is associated with increased risk of subsequent invasive breast cancer, yet little is known about the etiology of AH. Insulin-like growth factor binding protein 2 (IGFBP-2) may contribute to the development of AH due to its proliferative effects on mammary tissue. We conducted a nested case-control study of postmenopausal women enrolled in Women’s Health Initiative-Clinical Trial. Cases were 275 women who developed incident AH during follow-up, individually (1 : 1) matched to controls. Levels of IGFBP-2 were determined from fasting serum collected at baseline. Multivariable conditional logistic regression models were used to estimate odds ratios for the association of IGFBP-2 with risk of AH. Serum IGFBP-2 was associated with a nonsignificant decrease in risk for AH, when comparing the highest quartile to lowest quartile (OR = 0.65; 95% CI = 0.32–1.31). This decrease in risk was most evident when analyses were restricted to nondiabetic, nonusers of hormone therapy (OR = 0.33, 95% CI = 0.13–0.86, ptrend = 0.06) and nondiabetic women who were overweight or obese (OR = 0.43, 95% CI = 0.18–1.03, ptrend = 0.05). Results from this study provide some support for an inverse association between serum IGFBP2 levels and risk of AH, particularly in nondiabetic women who are overweight or obese. Further studies are required to confirm these results.